In fact, the few schools that do have laboratories lack the necessary apparatus, chemical solutions, specimen samples and scientific equipment, forcing matriculation students to approach the ...

Mesoblast (ASX:MSB) was the top performer for the year up 835% (as of December 30). On December 18 Mesoblast announced that the US Food and Drug Administration (FDA) had finally approved its therapy ...